Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine

Oshiro, Telma Miyuki; Silva, Laís Teodoro da; Ortega, Marina Mazzilli; Perazzio, Sandro Félix; Duarte, Alberto José da Silva; Carneiro‐Sampaio, Magda

doi:10.1016/j.clinsp.2022.100007

Cited by 6 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eleven of 17 patients with humoral deficiencies in our study opted for CoronaVac. Whole-virion inactivated vaccines could elicit T cell response against other structural proteins such as N and M unelicited by S-only mRNA vaccines ( 20 , 39 ), which correlate with protection against severe disease and infection ( 40 , 41 ), and are not susceptible to mutations in Omicron ( 29 ). In our patients with humoral immunodeficiencies and no breakthrough COVID-19, 4 out of 5 patients in our study had a detectable SNM-specific IFN-γ + CD4 + T cell response after just 2 doses of CoronaVac; the single patient who did not have a detectable IFN-γ + CD4 + T cell response had an IL-2 + CD4 + T cell response.…”

Section: Discussionmentioning

confidence: 99%

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

Leung

Duque

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. Intradermal vaccination was also studied. Thirty-nine patients were vaccinated, including 16 with homologous intramuscular 0.3ml BNT162b2 and 17 with homologous intramuscular 0.5ml CoronaVac. Two patients received 3 doses of intradermal 0.5ml CoronaVac, and 4 patients received 2 doses of intramuscular BNT162b2 and the third dose with intradermal BNT162b2. No safety concerns were identified. Inadequate S-RBD IgG and surrogate virus neutralization responses were found after 2 doses in patients with humoral immunodeficiencies and especially so against BA.1. Dose 3 of either vaccine increased S-RBD IgG response. T cell responses against SARS-CoV-2 antigens were detected in vaccinated IEI patients by intracellular cytokine staining on flow cytometry. Intradermal third dose vaccine led to high antibody response in 4 patients. The primary vaccination series of BNT162b2 and CoronaVac in adults and children with IEIs should include 3 doses for optimal immunogenicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

Leung

Duque

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Remarkably, all XLA patients evaluated developed speci c IFN-γ-dependent cellular immune response, which highlights that vaccination in this population, despite not generating antibody protection, may provide cellular protection. Other authors have also described that T-cell compartment is normal in these patients characterized by absent or very low frequency of peripheral mature B-cells [34,35].…”

Section: Discussionmentioning

confidence: 75%

COVID-19 vaccination responses with different vaccine platforms in patients with inborn errors of immunity

Erra¹,

Uriarte²,

Colado³

et al. 2022

Preprint

View full text Add to dashboard Cite

Patients with Inborn Errors of Immunity (IEI) in Argentina were encouraged to receive licensed Sputnik, AstraZeneca, Sinopharm, Moderna, and Pfizer vaccines, even though most of the data on available vaccines comes from trials conducted in healthy individuals. We aimed to evaluate the safety and immunogenicity of the different vaccines in IEI patients in Argentina. The study cohort included adults and pediatric IEI patients (n=118) and age-matched healthy-controls (HC) (n=37). Samples were collected before, 28+/-3 days after the first and the second dose of the vaccine. B-cell response was evaluated by measuring IgG anti-Spike(S)/ receptor binding domain (RBD) and anti-nucleocapsid(N) antibodies by ELISA. Neutralization antibodies were also assessed with an alpha-S protein-expressing pseudo-virus assay. The T-cell response was analyzed by IFN-γ secretion on S or N-stimulated PBMC by ELISPOT and the frequency of S-specific circulating T follicular-helper cells (TFH) was evaluated by flow cytometry. No moderate/severe vaccine-associated adverse events were observed. Regarding the antibody response, anti-S/RBD titers showed significant differences in both pediatric and adult IEI patients versus the age-matched HC cohort (p<0.05). Neutralizing antibodies were detected in 71/99 patients and were also significantly lower in the patient cohort than age-matched HC (p<0.01). Positive S-specific IFN-γ response was observed in 84.5% of IEI patients and 82.1% presented S-specific TFH cells. In conclusion, COVID-19 vaccines showed safety in IEI patients and, although immunogenicity was lower than HC, they showed specific anti-S/RBD IgG, neutralizing antibody titers and T-cell-dependent cellular immunity with IFN-γ secreting T-cells. These findings may guide the recommendation of vaccination in IEI patients to prevent COVID-19 disease .

show abstract

“…Remarkably, all XLA patients evaluated developed specific IFN-γ-dependent cellular immune responses, which highlights that vaccination in this population, despite not generating antibody protection, may provide cellular protection. Other authors have also described that the T cell compartment is normal in these patients, characterized by the absence or very low frequency of peripheral mature B cells [ 48 , 49 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity

et al. 2022

View full text Add to dashboard Cite

Patients with inborn errors of immunity (IEI) in Argentina were encouraged to receive licensed Sputnik, AstraZeneca, Sinopharm, Moderna, and Pfizer vaccines, even though most of the data of humoral and cellular responses combination on available vaccines comes from trials conducted in healthy individuals. We aimed to evaluate the safety and immunogenicity of the different vaccines in IEI patients in Argentina. The study cohort included adults and pediatric IEI patients ( n = 118) and age-matched healthy controls (HC) ( n = 37). B cell response was evaluated by measuring IgG anti-spike/receptor binding domain (S/RBD) and anti-nucleocapsid(N) antibodies by ELISA. Neutralization antibodies were also assessed with an alpha-S protein-expressing pseudo-virus assay. The T cell response was analyzed by IFN-γ secretion on S- or N-stimulated PBMC by ELISPOT and the frequency of S-specific circulating T follicular-helper cells (TFH) was evaluated by flow cytometry. No moderate/severe vaccine-associated adverse events were observed. Anti-S/RBD titers showed significant differences in both pediatric and adult IEI patients versus the age-matched HC cohort ( p < 0.05). Neutralizing antibodies were also significantly lower in the patient cohort than in age-matched HC ( p < 0.01). Positive S-specific IFN-γ response was observed in 84.5% of IEI patients and 82.1% presented S-specific TFH cells. Moderna vaccines, which were mainly administered in the pediatric population, elicited a stronger humoral response in IEI patients, both in antibody titer and neutralization capacity, but the cellular immune response was similar between vaccine platforms. No difference in humoral response was observed between vaccinated patients with and without previous SARS-CoV-2 infection. In conclusion, COVID-19 vaccines showed safety in IEI patients and, although immunogenicity was lower than HC, they showed specific anti-S/RBD IgG, neutralizing antibody titers, and T cell-dependent cellular immunity with IFN-γ secreting cells. These findings may guide the recommendation for a vaccination with all the available vaccines in IEI patients to prevent COVID-19 disease. Supplementary Information The online version contains supplementary material available at 10.1007/s10875-022-01382-7.

show abstract

Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine

Cited by 6 publications

References 17 publications

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

COVID-19 vaccination responses with different vaccine platforms in patients with inborn errors of immunity

COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity

Contact Info

Product

Resources

About

Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine

Cited by 6 publications

References 17 publications

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

­­­­­COVID-19 vaccination responses with different vaccine platforms in patients with inborn errors of immunity

COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity

Contact Info

Product

Resources

About

COVID-19 vaccination responses with different vaccine platforms in patients with inborn errors of immunity